Biohaven Pharmaceutical Holding Co Ltd (BHVN) Insider Robert Berman Sells 35,000 Shares

Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) insider Robert Berman sold 35,000 shares of the stock in a transaction dated Wednesday, January 10th. The shares were sold at an average price of $27.52, for a total transaction of $963,200.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Robert Berman also recently made the following trade(s):

  • On Tuesday, December 19th, Robert Berman sold 10,000 shares of Biohaven Pharmaceutical stock. The shares were sold at an average price of $24.10, for a total transaction of $241,000.00.
  • On Monday, December 11th, Robert Berman sold 25,000 shares of Biohaven Pharmaceutical stock. The shares were sold at an average price of $21.28, for a total transaction of $532,000.00.
  • On Thursday, November 9th, Robert Berman sold 27,423 shares of Biohaven Pharmaceutical stock. The shares were sold at an average price of $26.60, for a total transaction of $729,451.80.
  • On Tuesday, November 14th, Robert Berman sold 160,000 shares of Biohaven Pharmaceutical stock. The shares were sold at an average price of $25.76, for a total transaction of $4,121,600.00.

Shares of Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) traded up $0.35 on Monday, hitting $32.41. 579,057 shares of the company’s stock traded hands, compared to its average volume of 420,220. Biohaven Pharmaceutical Holding Co Ltd has a one year low of $17.00 and a one year high of $39.51. The firm has a market capitalization of $1,170.00 and a PE ratio of -6.21.

Biohaven Pharmaceutical (NYSE:BHVN) last announced its earnings results on Tuesday, November 14th. The company reported ($1.19) EPS for the quarter, topping the consensus estimate of ($1.22) by $0.03. equities research analysts forecast that Biohaven Pharmaceutical Holding Co Ltd will post -6.4 earnings per share for the current fiscal year.

Several institutional investors and hedge funds have recently made changes to their positions in BHVN. Deschutes Portfolio Strategy LLC acquired a new position in shares of Biohaven Pharmaceutical in the third quarter worth about $374,000. Strs Ohio acquired a new position in shares of Biohaven Pharmaceutical in the third quarter worth about $680,000. Nationwide Fund Advisors acquired a new position in shares of Biohaven Pharmaceutical in the third quarter worth about $214,000. Emerald Advisers Inc. PA acquired a new position in shares of Biohaven Pharmaceutical in the third quarter worth about $9,096,000. Finally, Emerald Mutual Fund Advisers Trust acquired a new position in shares of Biohaven Pharmaceutical in the third quarter worth about $7,483,000. Institutional investors own 47.76% of the company’s stock.

Several equities analysts have recently weighed in on the stock. Zacks Investment Research lowered shares of Biohaven Pharmaceutical from a “hold” rating to a “sell” rating in a research report on Tuesday, January 30th. Canaccord Genuity assumed coverage on shares of Biohaven Pharmaceutical in a research report on Friday, December 15th. They set a “buy” rating and a $30.00 price objective for the company. Piper Jaffray Companies set a $48.00 price objective on shares of Biohaven Pharmaceutical and gave the company a “buy” rating in a research report on Monday, December 11th. Needham & Company LLC restated a “buy” rating and set a $36.00 price objective on shares of Biohaven Pharmaceutical in a research report on Wednesday, November 15th. Finally, BidaskClub lowered shares of Biohaven Pharmaceutical from a “sell” rating to a “strong sell” rating in a research report on Tuesday, November 14th. Two analysts have rated the stock with a sell rating and six have assigned a buy rating to the company. The stock has an average rating of “Buy” and an average price target of $36.14.

COPYRIGHT VIOLATION NOTICE: This report was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this report on another website, it was illegally stolen and republished in violation of international copyright laws. The correct version of this report can be read at https://www.dispatchtribunal.com/2018/02/05/robert-berman-sells-35000-shares-of-biohaven-pharmaceutical-holding-co-ltd-bhvn-stock.html.

Biohaven Pharmaceutical Company Profile

Biohaven Pharmaceutical Holding Company Ltd. is a United States-based biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. It has a portfolio of multiple late-stage drug candidates.

Insider Buying and Selling by Quarter for Biohaven Pharmaceutical (NYSE:BHVN)

Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply